Ars Pharmaceuticals, Inc. (SPRY)
NASDAQ:SPRY
Want to see SPRY full AI Analyst Report?
SPRY Stock Chart & Stats
$8.30
-$0.02(-0.18%)
At close: 4:00 PM EST
$8.30
-$0.02(-0.18%)
Day’s Range― - ―
52-Week Range$6.66 - $18.90
Previous CloseN/A
Volume456.05K
Average Volume (3M)1.88M
Market Cap
$883.80M
Enterprise Value$973.47M
Total Cash (Recent Filing)$200.97M
Total Debt (Recent Filing)$97.11M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Aug 12, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.01
Shares Outstanding99,303,260
10 Day Avg. Volume2,027,507
30 Day Avg. Volume1,884,640
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)10.05
Price to Sales (P/S)13.63
P/FCF Ratio-6.71
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue9.83
Enterprise Value/Gross Profit12.75
Enterprise Value/Ebitda-5.01
Forecast
1Y Price Target
$28.33Price Target Upside241.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.58
Revenue Forecast (FY)$149.35M
Bulls Say, Bears Say
Bulls Say
High Product-level EconomicsSustained high gross margins (~75.8%) alongside TTM revenue growth (+17.5%) indicate attractive product economics for neffy. Durable unit-level profitability supports scalable margins as volume and payer access expand, improving long-term cash conversion if commercialization execution holds.
Rapid Commercial Adoption And Expanded AccessTriple-year prescription growth, a growing installed base (~120k patients), expanded 148-rep field force and ~90% commercial coverage materially raise the addressable market. These structural adoption gains and international approvals broaden durable refill and repeat-purchase dynamics critical to long-term revenue growth.
Meaningful Cash Runway And Breakeven PathA $201M cash balance plus a management plan targeting cash-flow breakeven by mid-2027 gives multi-quarter runway to scale refills, payor access and marketing. This funding window reduces immediate dilution pressure and allows continued investment in durable commercialization capabilities if execution remains on plan.
Bears Say
Severe Negative Operating Cash FlowPersistent negative operating cash flow (~-$175M TTM) and negative free cash flow reflect heavy ongoing burn to support commercialization and SG&A. Over a multi-quarter horizon this elevates funding risk and forces either rapid path-to-breakeven execution or dilutive financing, constraining strategic optionality.
Large Cumulative Losses And Weakened EquityVery large TTM net losses (~$198M) and a deeply negative net margin (~-203%) have eroded equity (~$61M) and depressed returns. Sustained losses limit balance-sheet flexibility and increase reliance on external funding or steep cost cuts to maintain operations and long-term commercialization investments.
Payer Friction And Prescription AbandonmentStructural payer barriers—~43% of covered lives still needing prior authorization, ~22–23% abandonment and high gross-to-net (~50%)—materially reduce realized uptake and durable revenue. Persistent access friction slows conversion of written scripts into repeat refills and constrains predictable, long-term revenue growth.
ARS Pharmaceuticals News
SPRY FAQ
What was Ars Pharmaceuticals, Inc.’s price range in the past 12 months?
Ars Pharmaceuticals, Inc. lowest stock price was $6.66 and its highest was $18.90 in the past 12 months.
What is Ars Pharmaceuticals, Inc.’s market cap?
Ars Pharmaceuticals, Inc.’s market cap is $883.80M.
When is Ars Pharmaceuticals, Inc.’s upcoming earnings report date?
Ars Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 70 days.
How were Ars Pharmaceuticals, Inc.’s earnings last quarter?
Ars Pharmaceuticals, Inc. released its earnings results on May 15, 2026. The company reported -$0.61 earnings per share for the quarter, missing the consensus estimate of -$0.516 by -$0.094.
Is Ars Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Ars Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Ars Pharmaceuticals, Inc. pay dividends?
Ars Pharmaceuticals, Inc. does not currently pay dividends.
What is Ars Pharmaceuticals, Inc.’s EPS estimate?
Ars Pharmaceuticals, Inc.’s EPS estimate is -0.48.
How many shares outstanding does Ars Pharmaceuticals, Inc. have?
Ars Pharmaceuticals, Inc. has 99,303,260 shares outstanding.
What happened to Ars Pharmaceuticals, Inc.’s price movement after its last earnings report?
Ars Pharmaceuticals, Inc. reported an EPS of -$0.61 in its last earnings report, missing expectations of -$0.516. Following the earnings report the stock price went down -6.486%.
Which hedge fund is a major shareholder of Ars Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in SPRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ARS Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.33 (241.37% Upside)
$28.33 (241.37% Upside)
Blogger Sentiment
Bullish
SPRY Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 339.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.45%
12-Months-Change
Fundamentals
Return on Equity
-153.61%
Trailing 12-Months
Asset Growth
-12.14%
Trailing 12-Months
Company Description
Ars Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
SPRY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and meaningful operational progress (robust YoY prescription and revenue growth, regulatory approvals, expanded coverage and new affordability programs), backed by a healthy cash balance and a clear plan to scale through the back-to-school season and refill cycles. However, execution risks remain: significant SG&A spend and cash burn, prior-authorization friction that still limits access for a meaningful portion of covered lives, notable prescription abandonment, and uncertainty around timing of key payer decisions (e.g., CVS Caremark). On balance, the positives around growth, access expansion, regulatory wins and commercial initiatives outweigh the operational challenges, but the company remains execution- and timing-dependent over the coming quarters.View all SPRY earnings summariesSPRY Stock 12 Month Forecast
Average Price Target
$28.33
▲(241.37% Upside)
Technical Analysis
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Pharming Group
―
Maze Therapeutics, Inc.
―
Sionna Therapeutics, Inc.
―
Ownership Overview
59.91% Insiders
8.29% Mutual Funds
11.65% Other Institutional Investors
10.87% Public Companies and
Individual Investors